Zymfentra Alternatives Compared
Zymfentra | Vedolizumab | Zeposia |
|
---|
Zymfentra (infliximab) | Vedolizumab | Zeposia (ozanimod) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Inflammatory Bowel Disease, Crohn's Disease, Crohn's Disease - Maintenance, Ulcerative Colitis, Ulcerative Colitis - Maintenance. Zymfentra may also be used for purposes not listed in... View more |
Prescription only
Prescribed for Crohn's Disease - Maintenance, Ulcerative Colitis, Crohn's Disease. vedolizumab may also be used for purposes not listed in this medication guide. |
Prescription only
Zeposia is an S1P receptor modulator that may be used to treat relapsing forms of multiple sclerosis or ulcerative colitis in adults. It requires a 7-day titration period and reduces lymphocyte... View more |
Related suggestions Ulcerative Colitis
|
|||||||
More about Zymfentra (infliximab) | More about Vedolizumab | More about Zeposia (ozanimod) | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Vedolizumab has an average rating of 6.1 out of 10 from a total of 172 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 29% reported a negative effect. |
Zeposia has an average rating of 8.0 out of 10 from a total of 6 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
See also: Zymfentra side effects in more detail. |
See also: vedolizumab side effects in more detail. |
See also: Zeposia side effects in more detail. |
||||||||
Generic Availability | ||||||||||
N/A |
N/A |
|||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Zeposia prices |
||||||||
Dosage Form(s) Available | ||||||||||
N/A |
N/A |
|
||||||||
Brand Names | ||||||||||
Other infliximab brands include: Avsola, Inflectra, Ixifi, Remicade, Renflexis | Entyvio, Entyvio Pen |
N/A |
||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
228 hours |
600 hours |
264 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 498 drugs are known to interact with Zymfentra:
|
A total of 152 drugs are known to interact with vedolizumab:
|
A total of 893 drugs are known to interact with Zeposia:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
October 20, 2023 |
May 20, 2014 |
March 25, 2020 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.